BHEL Supplies Medical Oxygen Plant in record time
In response to the critical situation arising out of shortage of medical oxygen in the second half of April '21, Bharat Heavy Electricals Limited (BHEL) has once again risen to the occasion by venturing into the manufacture of medical oxygen plants.
BHEL’s first Medical Oxygen plant developed and manufactured using CSIR-IIP technology was formally handed over to SLG Hospitals — Hyderabad, in a flagging off ceremony in the presence of CMD and senior officials of BHEL as well as SLG Hospitals at BHEL’s Hyderabad unit, in a record time of less than 35 days from receipt of order.
BHEL has signed an agreement with the Council of Scientific and Industrial Research—Indian Institute of Petroleum (CSIR-IIP) on 03.05.21 for transfer of technology for Medical Oxygen Plants of 500 LPM and higher using Pressure Vacuum Swing Adsorption (PVSA) technology. The agreement entails development and deployment of 500 LPM medical oxygen plants and design upscaling to 1000 LPM and more.
Work for development of a prototype was initiated on war footing in three of BHEL’s biggest manufacturing units (Hyderabad, Bhopal and Haridwar). In parallel, work on design upscaling of 1000 LPM was also taken up. The BHEL team, with the support of CSIR, quickly overcame the various challenges such as procurement of zeolite material and other components, as well as those faced in the manufacturing process.
The first prototype was completed by BHEL’s Hyderabad unit on 11.06.21 in record time of less than 40 days from the date of signing of the agreement. The company was able to successfully complete absorption of technology, procurement of materials and manufacture of the equipment in this short time. The design for a 1000 LPM medical oxygen plant has also been completed and the first prototype of this unit is also expected to be ready soon. Notably, BHEL has already received commercial orders for supply of both 500 LPM and 1000 LPM PVSA plants to state hospitals. The other two units of BHEL are also manufacturing this equipment on a fast track basis, and a total of 10 units are to be supplied in the month of July.
Deployment of these plants will further supplement the efforts initiated by the company during the second wave of Covid 19 towards supply of medical oxygen, wherein BHEL’s units located at Bhopal and Haridwar supplied over 5,75,000 cubic meters (~ 80,000 cylinders) of medical oxygen to hospitals in their vicinity. BHEL being the responsible corporate citizen it is, stands firm in its resolve to contribute wholeheartedly in meeting the nation's requirement to combat COVID-19.
MCX signs MOU with European Energy Exchange for Electricity Derivatives
Multi Commodity Exchange of India Ltd., India’s largest Exchange in the commodity derivatives segment, and European Energy Exchange AG (EEX) have entered into a Memorandum of Understanding (MOU), with the objective of knowledge sharing and exchanging of expertise on electricity derivative products
This MoU will facilitate cooperation between the two exchanges in areas such as knowledge sharing, education & training and organizing events in the domain of electricity derivatives.
EEX is a leading energy exchange in Europe, which develops, operates and connects secure, liquid and transparent markets for power and other energy products.
Mr. P.S. Reddy, Managing Director & CEO of MCX, said: "We are delighted to sign a MOU with European Energy Exchange AG (EEX). This is a mutually beneficial MOU between MCX and EEX that will enable us to understand each other's market better. I am confident that this alliance between the two institutions provides for a continuous exchange of knowledge, expertise and best practices. Moreover, such cooperation is important for an overall growth and development of the commodity markets, given the evolving and dynamic nature of global markets."
TCS Recognized as a Leader in Gartner Magic Quadrant for Worldwide SAP S/4HANA Application Services
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been positioned as a Leader in the Gartner Magic Quadrant for SAP S/4HANA Application Services, Worldwide
The report states that “The Magic Quadrant evaluated 20 service providers’ capabilities to deliver SAP S/4HANA application assessment, implementation and management services on a worldwide basis.” It goes on to say that “Leaders are performing well today, gaining traction and mind share in the market; they have a clear vision of market direction and are actively building competencies to sustain their leadership position in the market. Leaders have built a considerable S/4HANA track record and capabilities across multiple industries, geographies, deployment approaches or modules.”
“As a growth and transformation partner to leading enterprises across the world, TCS focuses on enabling sustainable, insights-driven digital transformations that improve customer experience, accelerate time-tomarket and maximize stakeholder value,” said Akhilesh Tiwari, Global Head, Enterprise Application Services, TCS. “We believe this positioning as a Leader is a reflection of our vision, investments in innovation and intellectual property, deep industry knowledge, expertise in intelligent technologies and the resultant market success.”
TCS offers a comprehensive suite of SAP services, including design thinking, advisory, innovation consulting, implementation, and other digital support services. TCS leverages its intellectual property (IP)-led assets and accelerators as part of a comprehensive approach to modernize enterprise businesses, helping them shape business ecosystems and adopt new business models in their perpetual growth and transformation journeys. Market differentiators include:
• TCS Enterprise Navigator™ – an integrated consulting-led framework that supports C-suite leaders in realizing perpetual value from their transformation initiatives and driving business growth enabled by TCS Crystallus™ and TCS ConvertCore.
• TCS Crystallus – a set of pre-configured industry and business solutions, contextualized to address specific industry requirements. TCS Crystallus encompasses TCS’ domain expertise, industry best practices, and contextual knowledge for S/4HANA greenfield implementation programs.
• TCS ConvertCore – offers a built-in modular approach that allows enterprises to drive continuous business value. TCS ConvertCore is a compelling proposition for enterprises to accelerate system conversion to SAP S/4HANA and pave a solid foundation for their perpetual transformation journey.
TCS helps customers evaluate newer digital offerings such as SAP S/4HANA, SAP® Customer Experience solutions, SAP SuccessFactors® solutions, SAP Ariba® solutions, and SAP® Business Technology Platform, to define their roadmap, architecture and strategy. TCS’ innovation and demo centers in Cincinnati-US, Paris, France, Mumbai-India and Tokyo-Japan help customers gain a first-hand experience of SAP’s new products and global innovations through a digital transformation ecosystem.
Wockhardt UK proudly hosts visit of HRH The Prince of Wales
Global pharmaceutical company Wockhardt UK, which has reserved capacity to allow for the supply of multiple vaccines to the UK government in its fight against COVID-19, was delighted to welcome His Royal Highness The Prince of Wales (Prince Charles) to its Wrexham manufacturing facility
Wockhardt UK specialises in the manufacture of sterile injectables and is one of the largest generic pharmaceutical companies in the UK with the capability to manufacture on a large-scale. Wockhardt is one of the major suppliers to the NHS and has had a site in Wrexham for over 20 years. It employs more than 500 people at the 612,000 sq. ft. high-tech factory.
While acknowledging the visit as a mark of honour, the Founder Chairman of Wockhardt Dr. Habil Khorakiwala said, “The visit today by His Royal Highness The Prince of Wales demonstrates recognition of our global strength in sterile injectable facilities and capacity. With four decades of expertise and experience behind us, we have been able to quickly rise to the occasion, scale up the manufacture of the vaccines and assist in mitigating the worldwide impact of COVID-19.”
Wockhardt UK has been instrumental in the manufacture of the Oxford/AstraZeneca COVID-19 vaccine and carries out the ‘fill and finish’ stage of the vaccine manufacturing process. The firm has a manufacturing contract with the UK Government in place until August 2022. This involves dispensing the COVID-19 vaccine into vials ready for it to be sent out across the country.
The visit comes eight months after Wockhardt welcomed Prime Minister Boris Johnson, who thanked staff for their hard work, saying that the vaccines could provide the “salvation for humanity.”
Dr. Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt adds, “We are delighted to showcase our innovation, talent and expertise at Wockhardt UK to His Royal Highness. We are committed to the cause and can be a key partner globally in fighting the world’s most demanding need of the hour during COVID-19.”
Ravi Limaye, Managing Director Wockhardt UK said, “It is a great honour to have His Royal Highness The Prince of Wales visit us today. We have been working at pace to ensure that our sophisticated sterile facility and our highly skilled workforce are geared up to manufacture the vaccines which have already been widely distributed to people across the UK.”
“To have His Royal Highness here to witness the pride and purpose of the Wockhardt team in Wrexham means so much to everyone.”